drugset / Trial / NCT00730405

Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis

NCT00730405 ↗

Phase 2 Completed 582 enrolled Stiefel, a GSK Company GlaxoSmithKline · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 2 study to examine how the study drug works and its side effects in subjects with toenail fungus.

Timeline

Start
2008-07-16
Primary completion
2010-02-19
Completion
2010-02-19

Drugs

EvaluationDrugModalityDoseRoute
Comparator Albaconazole Small molecule 100 mg Oral
Comparator Albaconazole Small molecule 200 mg Oral
Comparator Albaconazole Small molecule 400 mg Oral

Indications